Hvilken er prisen på 9 Meters Biopharma, Inc. (NMTR)

Prisen på 9 Meters Biopharma, Inc. (NMTR) er $0.0169

Hva er markedsverdien på 9 Meters Biopharma, Inc. (NMTR)

Markedsverdien på 9 Meters Biopharma, Inc. (NMTR) er $66.40K

9 Meters Biopharma, Inc. (NMTR) P/E-forhold

Based in Raleigh, North Carolina, 9 Meters Biopharma, Inc. operates as a clinical-stage biopharmaceutical company. Its core mission is to innovate treatments for individuals suffering from rare digestive conditions, gastrointestinal disorders with inadequate therapeutic options, and other severe debilitating ailments. The company's pipeline features several promising drug candidates. Larazotide, an 8-amino acid peptide, is currently in a Phase 3 clinical trial for the treatment of celiac disease and is also being assessed in a Phase IIa study for multi-system inflammatory syndrome. Another key asset, Vurolenatide, a long-acting injectable glucagon-like peptide-1, is undergoing Phase 2 clinical trials to address short bowel syndrome. Additionally, 9 Meters Biopharma is advancing other compounds, including NM-102, a small molecule peptide; NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist intended for the prevention of acute graft versus host disease; NM-136, a humanized monoclonal antibody designed to target specific obesity disorders; and NM-004, a double-cleaved mesalamine combined with an immunomodulator, slated for rare and/or orphan indications.

År	P/E-forhold	Endre
Ikke nok data for de angitte datoene.

År

P/E-forhold

Endre

Ikke nok data for de angitte datoene.

Selskap	P/E-forhold	Forskjell i P/E-forhold	Land
Vertex Pharmaceuticals Incorporated VRTX.US	28.05	-	US
Argenx SE ARGX.US	31.14	-	NL
Lonza Group AG LONN.SW	-	-	CH
Samsung Biologics Co.,Ltd. 207940.KS	-	-	KR
UCB S.A. UCB.BR	19.30	-	BE

Selskap

P/E-forhold

Forskjell i P/E-forhold

Land